23andMe initiates Phase 1 trial for 23ME-01473

23andMe Holding announced the first participant has been dosed in a Phase 1 clinical trial evaluating 23ME-01473 in advanced solid tumors. The target for the new investigational antibody, ULBP6, was discovered through 23andMe’s proprietary research platform, the world’s largest recontactable database of de-identified human genetic and phenotypic information. This is the third drug target genetically validated by the 23andMe research platform to enter the clinic in under 4 years. “Entering the clinic with this exciting new dual-mechanism NK-cell activator reinforces the ability of the 23andMe Therapeutics team, and the potential of our research platform, to discover and develop new therapies informed by human genetics,” said Jennifer Low, Head of Therapeutics Development, 23andMe. “We are excited to be underway in our study of ‘1473, and we are grateful to the patients participating in this trial.”